Anhco Nguyen Sells 5,241 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 5,241 shares of Atara Biotherapeutics stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $9.13, for a total transaction of $47,850.33. Following the transaction, the chief executive officer directly owned 137,837 shares in the company, valued at $1,258,451.81. The trade was a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock opened at $9.34 on Friday. The company’s 50 day simple moving average is $6.04 and its 200 day simple moving average is $8.93. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15. The firm has a market capitalization of $84.15 million, a price-to-earnings ratio of -13.94 and a beta of -0.30.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. Atara Biotherapeutics had a negative net margin of 40.91% and a negative return on equity of 79.12%. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.90 million. As a group, analysts predict that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current fiscal year.

Key Atara Biotherapeutics News

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Zacks highlighted that Atara Biotherapeutics’ stock has surged over the past month after the FDA outlined a regulatory pathway for tab-cel, reviving hopes for U.S. approval following two prior complete response letters. This is the main bullish driver behind recent momentum. Article Title
• Neutral Sentiment: Several firms, including Rosen Law Firm, Faruqi & Faruqi, Levi & Korsinsky, Pomerantz, Schall, Bronstein, Gewirtz & Grossman, and Bragar Eagel & Squire, issued reminders about a May 22 lead-plaintiff deadline in an already filed securities class action covering investors who bought shares between May 20, 2024 and January 9, 2026. The filings reiterate legal risk but do not add new operational details. Article Title
• Neutral Sentiment: Atara also disclosed insider sales by CEO Anhco Nguyen and CAO Yanina Grant-Huerta, but both transactions were reported as being made to cover tax withholding tied to equity vesting, which typically limits their significance as a negative signal. Article Title

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ATRA. Raymond James Financial Inc. acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at approximately $31,000. Dimensional Fund Advisors LP acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $181,000. Walleye Capital LLC acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $220,000. Quadrature Capital Ltd raised its holdings in shares of Atara Biotherapeutics by 22.8% in the fourth quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Atara Biotherapeutics by 33.8% in the third quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 6,622 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ATRA has been the topic of a number of research reports. Canaccord Genuity Group set a $13.00 price target on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Freedom Capital raised shares of Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Wall Street Zen raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.